Share
1,077 Posts.
lightbulb Created with Sketch. 92
clock Created with Sketch. 17/04/20
14:56
Share
Originally posted by RBx
↑
The FDA and other regulators around the world have been overwhelmed with applications to conduct COVID-related trials. Each application has to be assessed, as quickly as humanly possible, but it still takes time.Noxopharm has long known that inhibition of ENOX2 by Veyonda did not explain some of the beneficial results (such as abscopal responses) achieved by the drug, and it was only recently that the Hudson Institute discovered another aspect of its mechanism of action - one that appears suited to COVID treatment. Veyonda has proven in the LuPIN and DARRT trials that it is completely safe to use, so the authorities have nothing to lose if they give emergency approval for Veyonda to be used to treat seriously-ill COVID patients. It has been just over two weeks since the Noxopharm announcement. In that interval the company has had to write a comprehensive trial protocol, one that would have required extensive consultation with Intensive Care experts, for instance. It would have made urgent submissions to the FDA and others; made sure it had drug ready to be shipped around the world; and made arrangements for more to be manufactured.
Expand
With a worldwide cost amounting to Trillions of dollars, one thing is for certain. Noxopharm's submission to the FDA and other regulatory bodies will be examined.
(20min delay)